| Identification | Back Directory | [Name]
CNX-500 | [CAS]
1202758-21-1 | [Synonyms]
CNX-500
N1-(3-(3-((4-((3-acrylamidophenyl)amino)-5-methylpyrimidin-2-yl)amino)phenoxy)propyl)-N5-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)glutaramide
Pentanediamide, N1-[19-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-15-oxo-4,7,10-trioxa-14-azanonadec-1-yl]-N5-[3-[3-[[5-methyl-4-[[3-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]propyl]- | [Molecular Formula]
C48H68N10O9S | [MDL Number]
MFCD30533366 | [MOL File]
1202758-21-1.mol | [Molecular Weight]
961.18 |
| Hazard Information | Back Directory | [Uses]
CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC50 of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn[1]. | [References]
[1] Evans EK, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. DOI:10.1124/jpet.113.203489 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|